BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Caplin Point Laboratories Ltd. Q4 FY21 revenue grew 29.5% YoY to Rs 279 crore.
Ebitda margin improved 575 basis points YoY to 30.7% due to lower gross margin in the base year due to certain one-offs.
Subsequently, Ebitda grew 59.3% YoY to Rs 86 crore.
Profit after tax grew 35.8% YoY to Rs 66 crore due to lower other income.
On a full year basis, revenues, Ebitda and profit after tax grew 23%, 26% and 13%, respectively.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.